Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcRIIb
详细信息查看全文 | 推荐本文 |
摘要
Mast cells and basophils play a central role in allergy, asthma, and anaphylaxis, as well as in non-allergic inflammatory, neurological and autoimmune diseases. Allergen-mediated cross-linking of IgE bound to Fc蓻RI leads to cellular activation, and the low-affinity Fc receptor FcRIIb is a key inhibitor of subsequent degranulation. FcRIIb, when coengaged with Fc蓻RI via allergen bound to IgE, stimulates ITIM domain-mediated inhibitory signaling that efficiently suppresses mast cell and basophil activation. To assess the therapeutic potential of directed coengagement of Fc蓻RI and FcRIIb in the absence of Fc蓻RI crosslinking, we developed a fusion protein comprising the coupled Fc domains of murine IgE and human IgG1. As a key functional component of this tandem Fc蓻-Fc biologic, we engineered its IgG1 Fc domain to bind to human FcRIIb with 100-fold enhanced affinity relative to native IgG1 Fc. Using mast cells from mice transgenic for human FcRIIb, we show that this tandem Fc binds with high affinity to murine Fc蓻RI and human FcRIIb on mast cells, triggers phosphorylation of FcRIIb, and inhibits Fc蓻RI-dependent calcium mobilization. Control tandem Fc biologics containing a native IgG1 Fc domain or lacking binding to Fc receptors were markedly less active, demonstrating that the affinity-optimized tandem Fc can inhibit degranulation through stimulation of FcRIIb signaling as well as through competition with allergen-IgE immune complex for Fc蓻RI binding. We propose that in the context of a fully human tandem Fc biologic, high-affinity coengagement of Fc蓻RI and FcRIIb has potential as a novel therapy for allergy and other mast cell and basophil-mediated pathologies.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700